Skip to main content
Premium Trial:

Request an Annual Quote

NEWSBRIEF: Qiagen Posts 12% Rise in Sales in Q1

SAN FRANCISCO, May 6 - Qiagen today reported a 12 percent increase in sales.


Net sales for the first quarter ended March 31 came in at $70.5 million compared with $63.1 million one year ago. The company's $2 million in sales to Xeragon, which it acquired in April, are not included in the sales figures, according to Qiagen.


Net income for the quarter, excluding the effects of the Xeragon acquisition, increased to $10.5 million, or $.07 diluted earnings per share, compared with $8 million, or $0.6 per share, for the year-ago period, according to the company. With the results of the acquisition included for both periods, the company reported a rise in net income to $9.5 million for the first quarter, or diluted earnings per share of $.07, compared with $6 million, or $.04 per share, for the year-ago period.


R&D spending decreased slightly to $6.4 million compared to $6.7 million for the first quarter in 2001.


Qiagen said it had roughly $43 million in cash and cash equivalents as of March 31.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more